May 18th, 2016 by FFB Canada
Click here to download a printable version this article/fact sheet: PDF/Word.
What is a retinal prosthesis? A retinal prosthesis is a non-living, electronic substitute for the retina. Popular and brand names for retinal prostheses are the Bionic Eye and the Argus II. The aim is to restore vision to someone blinded by retinal eye disease. A retinal prosthesis is different from an implanted lens or a low-vision device, which works to maximize a persons existing vision.
What does it do? In people with advanced retinal disease, the light-capturing cells of the retina, called photoreceptors, have been lost, but the network of nerves that sends visual information to the brain often is intact. A retinal prosthesis bypasses the photoreceptors and sends visual signals to the brain.
Will it restore my vision? The prostheses that have been tested so far do not provide natural sight. For example, people who are using them are able to recognize a doorway or the shape of a person, or in some cases can make finer distinctions, such as the difference between a fork and a spoon. These retinal prostheses provide a simulation of sight which means that the users have to re-learn how to see. Their brains need to learn how to interpret this new kind of information.
Who could use it? Retinal prostheses are intended for people who are blind or have only minimal light perception, but who once had sight. With prostheses, the brain must interpret the devices signals. Someone blind from birth never developed this capacity, and therefore it might not benefit them.
Are any approved in Canada? Yes. The Argus II Retinal Prosthesis is approved by Health Canada. It is also approved in Europe and the USA. The Foundation Fighting Blindness played a key role in bringing the Argus II (sometimes called the Bionic Eye) to Canada by helping to fund an observational clinical trial of the device at the Toronto Western Hospital led by Dr. Robert Devenyi.
What will it cost? The Argus II Retinal Prosthesis is now being marketed in Europe for about $100,000 USD, plus the cost of the surgery to implant it. Second Sight (the manufacturer) is actively seeking coverage of the device through public insurance or government subsidies. The costs of other retinal prostheses are not yet known.
How does it work? Just as there are multiple kinds of smart phones, there are different approaches to this technology.
Camera + Epi-Retinal Chip The Argus II by Second Sight is the leader in this category. It captures images with a mini-camera embedded in glasses that also carry a batterypack. A 2D array of many tiny electrodes is implanted surgically on the front surface of the retina (epi-retinal). Images from the camera are converted into electrical pulses sent wirelessly to the implant. The pulses stimulate the retinas remaining cells to send patterns of nerve impulses, representing the images, along the optic nerve to the brain. Patients can learn to interpret the patterns and regain some functional vision. Most of the people who have received an Argus II implant have had some visual perception restored, allowing them to better orient themselves in a room or negotiate daily tasks. There appear to be significant variations in results between users.
The Intelligent Retinal Implant System is another camera/chip combo, similar to the Argus II. It is in clinical trials in Germany and the UK. Bionic Vision Australia is also working on a similar product.
Sub-Retinal Chip Retinal Implant AG has created a sub-retinal implant, which sits behind the retina instead of in front of it. This electronic chip contains tiny photocells to capture light, amplifiers to boost their signal, and electrodes to stimulate retinal nerve cells. Since photocells are part of the chip, the device does not need an external camera, and the sub-retinal placement should be more secure and stable than the epi-retinal option; but morecomplicated surgery is required to implant it. Clinical trials of this device are ongoing in Germany, Italy and the UK, and in the USA.
Other groups developing chips include Artificial Silicon Retina Microchip, the Boston Retinal Implant Project, and Nano Vision although the later two are not yet at the human trial stage.
Sub-retinal chips may allow somewhat higher resolution images than epi-retinal chips. However, since even the tiniest electrodes in these prostheses are bound to stimulate more than one retinal cell, so the wearers visual acuity may never approach normal sight. This limitation has led to hybrid strategies, in which remaining retinal nerve cells are made light-sensitive andthen stimulated by patterns of light instead of electricity.
Encoding Neural Signals Dr. Sheila Nirenberg of Cornell University is one of several researchers, who are developing this new hybrid approach to prosthetics. In Dr. Nirenbergs studies, a camera sends images to a computer, which measures local differences in intensity across the image and encodes this information in pulses of light that mimic the natural language of the central nervous system. The size of these pulses of light can be smaller than the smallest retinal nerve cells; they can be projected through the pupil onto individual retinal cells. Using a new approach called optogenetics, a form of gene therapy endows these nerve cells with the ability to respond directly to light, so that the computer-generated light pulses stimulate them to send high-resolution, realistic image representations to the brain. This approach is being tested in animals. If it proves to be effective, it should provide much higher-quality images and a more natural visual experience. Dr. Gautam Awatramani at the University of Victoria is one scientist funded by the Foundation Fighting Blindness donors to study similar therapies.
Direct to Brain Prothesis Scientists at the Monash Vision Group in Australia have developed a different type of vision prosthesis. It avoids the retina altogether. This device uses a video camera to capture images and send its electronic signals directly to the visual cortex of the brain.
While brain surgery sounds like a more difficult, and risky option, the surgery required is relatively straightforward. More importantly, if it is successful, the device could have some important advantages. For example, it could help people with retinal degenerative disease, but it might also help people whose optic nerve has been damaged due to glaucoma or injury
As well, this prosthesis would not be implanted into the retina and thus would not block or damage retinal tissue. So the prosthetic could be used to augment vision for people with some remaining sight, and would not impair their remaining vision. The Monash Vision Group and its partners have committed to having their direct to brain bionic eye ready for first patient tests very soon.
Updated May 18, 2016: Dr. Mary Sunderland, Director of Research & Education, Foundation Fighting Blindness. Initially reviewed by Dr. Bill Stell, Professor of Cell Biology and Anatomy, at the University of Calgary and Dr. Gautam Awatramani, University of Victoria.
Read the original post:
Everything You Need To Know About The Bionic Eye - The ...
- The Architecture of the Human Fovea Webvision - November 8th, 2021
- The Role of Reproductive Hormones in Postpartum Depression - November 8th, 2021
- 'Limb vs. Tail' lecture articulates variations of axolotl regeneration during research development The Maine Campus - The Maine Campus - November 8th, 2021
- Century Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Host Virtual Research & Development Update -... - November 8th, 2021
- Clade Therapeutics Raises $87 Million Series A Financing to - GlobeNewswire - November 8th, 2021
- Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent ... - The Bakersfield Californian - November 8th, 2021
- NextCure Reports Third Quarter 2021 Financial Results and Provides Business Update - Yahoo Finance - November 8th, 2021
- Bristol Myers Squibb to Highlight More than 80 Abstracts at ASH 2021 Demonstrating Strength of Innovative Therapeutic Platforms Improving Outcomes for... - November 8th, 2021
- Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of... - November 8th, 2021
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results - GlobeNewswire - November 8th, 2021
- UVA Science and Engineering Faculty Win 12 NSF Career Awards - University of Virginia - November 8th, 2021
- MAGENTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - marketscreener.com - November 8th, 2021
- Ronawk using stem cell tech developed at Olathe lab to advance liver cancer research in Turkey - Startland News - October 5th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WSAW - October 5th, 2021
- Researching the Safety and Effectiveness of Stem Cells to Treat 'Long Covid' - Entrepreneur - October 5th, 2021
- Global Hemoglobinopathies Markets, 2021-2028 - High Unmet Needs / Increasing R&D Investment / Initiatives to Improve Disease Awareness -... - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - KY3 - October 5th, 2021
- Stanford neuroscientist's 'assembloids' pave the way for innovative brain research - Scope - October 5th, 2021
- Exosome therapeutic Market 2021 is Showing Impressive Growth by 2028 | Trends, Share, Size, Top Key Players Analysis and Forecast Research EcoChunk -... - October 5th, 2021
- BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa - WWNY - October 5th, 2021
- Cell Based Assay & High Content Screening Market Report 2021: The Workhorse of the Pharmaceutical Industry is Becoming a Central Player in... - October 5th, 2021
- Advancing the Development of Innovative Veterinary Products - FDA.gov - October 5th, 2021
- Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial - WBKO - October 5th, 2021
- $500K Grant Supports Research on Muscle Growth in Pigs, With Broader Health Implications - Maryland Today - July 22nd, 2021
- EU approves bluebird bio's CALD gene therapy Skysona - PMLiVE - July 22nd, 2021
- Secrets and pies: the battle to get lab-grown meat on the menu - The Guardian - July 22nd, 2021
- Biomedical Warming and Thawing Devices Market Revenue to Cross USD 308 Mn by 2027: Global Market Insights Inc. - Markets Insider - July 22nd, 2021
- A Recovery for All Of Us: New York City Invests $1 Billion in Life Sciences - Brooklyn Daily Eagle - July 22nd, 2021
- The growing global "infodemic" around stem cell therapies - Axios - June 25th, 2021
- NanoString Launches nCounter Stem Cell Characterization Panel to Advance the Development of Stem Cell Therapy - Yahoo Finance - June 25th, 2021
- Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies - Yahoo... - June 25th, 2021
- Immusoft Announces Formation of Scientific Advisory Board - Business Wire - June 25th, 2021
- Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene... - June 25th, 2021
- Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy... - June 25th, 2021
- More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities - PRNewswire - June 25th, 2021
- Andrs Garca Receives Distinguished Professor Award | Research - Research Horizons - June 25th, 2021
- Local foundation awards $1.25 million to MIND Institute to study rare genetic condition - UC Davis Health - June 25th, 2021
- MeCP2 is a microsatellite binding protein that protects CA repeats from nucleosome invasion - Science Magazine - June 25th, 2021
- The Stem Cell Manufacturing market is projected to reach USD 18.0 billion by 2026 from USD - GlobeNewswire - May 28th, 2021
- Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic... - May 28th, 2021
- Global Flow Cytometry Market (2020 to 2026) - by Technology, Product and Service, Application, End-user and Geography - ResearchAndMarkets.com -... - May 28th, 2021
- Meso-Brain project explores 3D printed stem cells to treat neurological conditions - 3D Printing Industry - May 28th, 2021
- Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Fourth Annual Science Day - Business Wire - May 28th, 2021
- GPB Scientific Announces Additional Growth Financing to Support Commercialization of Curate Cell Processing System for Next-Generation Cell & Gene... - May 28th, 2021
- TScan Therapeutics Adds to Executive Leadership Team and Board of Directors - BioSpace - May 28th, 2021
- Bone Therapeutics Provides First Quarter 2021 Business Update - GlobeNewswire - May 28th, 2021
- Merakris Therapeutics, Inc. Announces FDA Clearance for - GlobeNewswire - May 28th, 2021
- Stem Cell Manufacturing Market 2021 | Research With Size, Growth, Manufacturers, Key Segment, Analysis, Development Status, Segments and 2027... - February 19th, 2021
- Tissue regeneration: Reserve or reverse? - Science Magazine - February 19th, 2021
- Global Scaffold Technology Market Is Expected to Reach USD 2.16 billion by 2028 : Fior Markets - GlobeNewswire - February 19th, 2021
- Recombinant Growth Factors to Account for Over 45% of Overall Demand through 2031: Persistence Market Research - PRNewswire - February 19th, 2021
- The Untapped Potential of Cell and Gene Therapy - AJMC.com Managed Markets Network - February 19th, 2021
- Century Therapeutics Significantly Expands Capabilities with New Operational, Laboratory and Manufacturing Facilities in Pennsylvania and New Jersey -... - February 19th, 2021
- Cell Therapy Processing Market To Grow Value $12062 Million By 2026 | Latest Research Report - PharmiWeb.com - February 19th, 2021
- Global Stem Cell Therapy Market 2020 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2025 KSU | The Sentinel... - February 19th, 2021
- Humanized Mouse and Rat Model Market: Increased development of monoclonal antibodies and improved healthcare to drive the market - BioSpace - February 19th, 2021
- Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings - PRNewswire - February 19th, 2021
- Global Apoptosis Assays Market Estimated To Expand At A Robust CAGR By 2027||Promega, Abcam plc, Research And Diagnostic Systems, Inc., Sartorius AG,... - February 19th, 2021
- Tibidabo Scientific Industries Strengthens its Core Executive Team with the Appointment of Industry Veteran, John LaViola as Chief Technology Officer... - February 19th, 2021
- Global Cell Expansion Market Value Projected to Expand by 2021-2026 | Thermo Fisher Scientific, Inc., GE Healthcare, Lonza Group Ltd., Becton,... - February 19th, 2021
- How Irish medtech came to thrive - Med-Tech Innovation - February 19th, 2021
- Translational Regenerative Medicine Market: Immunotherapy is projected to be the fastest growing segment during the forecast period - BioSpace - February 11th, 2021
- Ensoma Launches to Pioneer Next-Generation In Vivo Approach to Deliver First Off-the-shelf Genomic Medicines - Business Wire - February 11th, 2021
- Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies - PRNewswire - February 11th, 2021
- Global Biopreservation Market Is Expected to Reach USD 7.67 Billion by 2028 : Fior Markets - GlobeNewswire - February 11th, 2021
- Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater... - February 11th, 2021
- Stem Cell Therapy Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast By 2029: Osiris Therapeutics, NuVasive, Chiesi... - February 11th, 2021
- 2020 Outlook on the Global Singlecell Technology Industry - Market Size was Over $800 Million in 2019 - ResearchAndMarkets.com - Business Wire - February 11th, 2021
- Stem Cell Cryopreservation Equipments Market Size Report: Strategies of Key Manufacturers, Project Investment of New Industries: Chart, Worthington... - February 11th, 2021
- Seattle Cancer Care Alliance Celebrates 20 Years of Innovation in Cancer Treatment and Care - Business Wire - February 11th, 2021
- Outlook on the CRISPR Gene Editing Global Market to 2030 - Analysis and Forecasts - GlobeNewswire - February 11th, 2021
- Researchers curb local immune response in horses receiving stem cell injury therapy - Horsetalk - February 7th, 2021
- Biobanking Market Report Research and Global Outlook 2021 to 2025 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - February 7th, 2021
- Animal Stem Cell Therapy Market By Product Type (Dogs, Horses) And By End-Users/Application (Veterinary Hospitals, Research Organizations) Market... - February 6th, 2021
- Stem Cell Assay Market Share, Demand, Manufacturers and Forecast till 2027 | Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent... - February 6th, 2021
- Global Apoptosis Assays Market Set To Grow At Healthy CAGR Of 11.10% By 2027||Abcam plc, Research And Diagnostic Systems, Inc., Sartorius AG, Biotium,... - February 6th, 2021
- Jill Biden signals White House resolve on cancer research: This is the fight of our lives - The Cancer Letter - February 6th, 2021
- Tiny sensor technique reveals cellular forces involved in tissue generation - Brown University - February 6th, 2021
- Global Stem Cell Partnering Terms and Agreements Directory 2020: Company AZ, Headline Value, Stage of Development at Signing, Deal Component Type,... - February 6th, 2021
- Perales Examines the Impact of COVID-19 on Recipients of Cellular Therapies for Cancer - OncLive - February 6th, 2021